270 related articles for article (PubMed ID: 31862804)
1. Radiohybrid Ligands: A Novel Tracer Concept Exemplified by
Wurzer A; Di Carlo D; Schmidt A; Beck R; Eiber M; Schwaiger M; Wester HJ
J Nucl Med; 2020 May; 61(5):735-742. PubMed ID: 31862804
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and pre-clinical evaluation of a new class of high-affinity
Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Preclinical Evaluation of
Wurzer A; Kunert JP; Fischer S; Felber V; Beck R; Rose F; D'Alessandria C; Weber W; Wester HJ
J Nucl Med; 2022 Oct; 63(10):1489-1495. PubMed ID: 35086894
[TBL] [Abstract][Full Text] [Related]
4. Preclinical comparison of four [
Wurzer A; Parzinger M; Konrad M; Beck R; Günther T; Felber V; Färber S; Di Carlo D; Wester HJ
EJNMMI Res; 2020 Dec; 10(1):149. PubMed ID: 33284394
[TBL] [Abstract][Full Text] [Related]
5. Automated synthesis of [
Wurzer A; Di Carlo D; Herz M; Richter A; Robu S; Schirrmacher R; Mascarin A; Weber W; Eiber M; Schwaiger M; Wester HJ
EJNMMI Radiopharm Chem; 2021 Jan; 6(1):4. PubMed ID: 33484364
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. Development of
Potemkin R; Strauch B; Kuwert T; Prante O; Maschauer S
Mol Pharm; 2020 Mar; 17(3):933-943. PubMed ID: 32011889
[TBL] [Abstract][Full Text] [Related]
8. In Vitro and In Vivo Characterization of an
Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S
J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.
Schottelius M; Wurzer A; Wissmiller K; Beck R; Koch M; Gorpas D; Notni J; Buckle T; van Oosterom MN; Steiger K; Ntziachristos V; Schwaiger M; van Leeuwen FWB; Wester HJ
J Nucl Med; 2019 Jan; 60(1):71-78. PubMed ID: 30237214
[TBL] [Abstract][Full Text] [Related]
10. In Vivo Evaluation of ¹⁸F-SiFAlin-Modified TATE: A Potential Challenge for ⁶⁸Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET.
Niedermoser S; Chin J; Wängler C; Kostikov A; Bernard-Gauthier V; Vogler N; Soucy JP; McEwan AJ; Schirrmacher R; Wängler B
J Nucl Med; 2015 Jul; 56(7):1100-5. PubMed ID: 25977461
[TBL] [Abstract][Full Text] [Related]
11. One-Step
Kuo HT; Lepage ML; Lin KS; Pan J; Zhang Z; Liu Z; Pryyma A; Zhang C; Merkens H; Roxin A; Perrin DM; Bénard F
J Nucl Med; 2019 Aug; 60(8):1160-1166. PubMed ID: 30737299
[TBL] [Abstract][Full Text] [Related]
12. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
[TBL] [Abstract][Full Text] [Related]
13. Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using
Yusufi N; Wurzer A; Herz M; D'Alessandria C; Feuerecker B; Weber W; Wester HJ; Nekolla S; Eiber M
J Nucl Med; 2021 Aug; 62(8):1106-1111. PubMed ID: 33443072
[TBL] [Abstract][Full Text] [Related]
14. Matched-Pair Comparison of
Kroenke M; Mirzoyan L; Horn T; Peeken JC; Wurzer A; Wester HJ; Makowski M; Weber WA; Eiber M; Rauscher I
J Nucl Med; 2021 Aug; 62(8):1082-1088. PubMed ID: 33277394
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
[TBL] [Abstract][Full Text] [Related]
16. Validation of a [Al
Al-Momani E; Israel I; Samnick S
Appl Radiat Isot; 2017 Dec; 130():102-108. PubMed ID: 28950199
[TBL] [Abstract][Full Text] [Related]
17. A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy.
Yang T; Peng L; Qiu J; He X; Zhang D; Wu R; Liu J; Zhang X; Zha Z
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2331-2341. PubMed ID: 36864362
[TBL] [Abstract][Full Text] [Related]
18.
Young JD; Abbate V; Imberti C; Meszaros LK; Ma MT; Terry SYA; Hider RC; Mullen GE; Blower PJ
J Nucl Med; 2017 Aug; 58(8):1270-1277. PubMed ID: 28408532
[TBL] [Abstract][Full Text] [Related]
19. Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational Approach.
Lahnif H; Grus T; Pektor S; Greifenstein L; Schreckenberger M; Rösch F
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770742
[TBL] [Abstract][Full Text] [Related]
20. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]